Polycystic Ovary Syndrome Treatment Market, By Drug Class (Oral contraceptives, Insulin Sensitizing Agents, Anti-Depressants, Ornithine Decarboxylase Inhibitors, Aromatase Inhibitors & SERMs, Diuretics), By Distribution Channel (Hospital Pharmacies, Retai

Polycystic Ovary Syndrome Treatment Market, By Drug Class (Oral contraceptives, Insulin Sensitizing Agents, Anti-Depressants, Ornithine Decarboxylase Inhibitors, Aromatase Inhibitors & SERMs, Diuretics), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Polycystic ovary syndrome can be explained as set of symptoms such as insulin sensitivity, menstrual regulatory, infertility, acne, and excess body and facial hair, which occurs due to increased levels of male hormone i.e. androgens in females of child-bearing age (15 to 49 years). Polycystic ovary syndrome is an incurable diseases, however, it can be managed by various options such as lifestyle changes, reducing weight, and taking medicines.
Restraints of the Global Polycystic Ovary Syndrome Treatment Market
Major factors hampering the growth of the polycystic ovary syndrome treatment market during the forecast period constitutes of unavailability of FDA approved drugs, and alternative treatment options.
Key features of the study:
This report provides in-depth analysis of the global polycystic ovary syndrome treatment market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021, as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
It profiles leading players in the global polycystic ovary syndrome treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Sanofi, Novartis AG, Teva Pharmaceutical Industries Limited, Addex Therapeutics Ltd., BIOCAD, Merck & Co., Inc., AstraZeneca plc., Bristol Myers Squibb Co., Ferring Pharmaceuticals, Inc., and Crinetics Pharmaceuticals, Inc.
Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
The global polycystic ovary syndrome treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.
Detailed Segmentation
Global Polycystic Ovary Syndrome Treatment Market, By Drug Class:
Oral contraceptives
Insulin Sensitizing Agents
Anti-Depressants
Ornithine Decarboxylase Inhibitors
Aromatase Inhibitors & SERMs
Diuretics
Global Polycystic Ovary Syndrome Treatment Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Polycystic Ovary Syndrome Treatment Market, By Geography:
North America
By Drug Class
Oral contraceptives
Insulin Sensitizing Agents
Anti-Depressants
Ornithine Decarboxylase Inhibitors
Aromatase Inhibitors & SERMs
Diuretics
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.S.
Canada
Europe
By Drug Class
Oral contraceptives
Insulin Sensitizing Agents
Anti-Depressants
Ornithine Decarboxylase Inhibitors
Aromatase Inhibitors & SERMs
Diuretics
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
By Drug Class
Oral contraceptives
Insulin Sensitizing Agents
Anti-Depressants
Ornithine Decarboxylase Inhibitors
Aromatase Inhibitors & SERMs
Diuretics
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
By Drug Class
Oral contraceptives
Insulin Sensitizing Agents
Anti-Depressants
Ornithine Decarboxylase Inhibitors
Aromatase Inhibitors & SERMs
Diuretics
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Middle East:
By Drug Class
Oral contraceptives
Insulin Sensitizing Agents
Anti-Depressants
Ornithine Decarboxylase Inhibitors
Aromatase Inhibitors & SERMs
Diuretics
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
GCC
Israel
Rest of Middle East
Africa
By Drug Class
Oral contraceptives
Insulin Sensitizing Agents
Anti-Depressants
Ornithine Decarboxylase Inhibitors
Aromatase Inhibitors & SERMs
Diuretics
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region:
Central Africa
South Africa
North Africa
Company Profiles
Sanofi Plc*
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
Novartis AG
Teva Pharmaceutical Industries Limited
Addex Therapeutics Ltd.
BIOCAD
Merck & Co., Inc.
AstraZeneca plc.
Bristol Myers Squibb Co.
Ferring Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc.
“*” marked represents similar segmentation in other categories in the respective section.